Equity-efficiency trade-offs associated with alternative approaches to deceased donor kidney allocation : a patient-level simulation by Li, Bernadette et al.
  
 
 
 
warwick.ac.uk/lib-publications 
 
 
 
 
 
Manuscript version: Author’s Accepted Manuscript 
The version presented in WRAP is the author’s accepted manuscript and may differ from the 
published version or Version of Record. 
 
Persistent WRAP URL: 
http://wrap.warwick.ac.uk/122785                                                        
 
How to cite: 
Please refer to published version for the most recent bibliographic citation information.  
If a published version is known of, the repository item page linked to above, will contain 
details on accessing it. 
 
Copyright and reuse: 
The Warwick Research Archive Portal (WRAP) makes this work by researchers of the 
University of Warwick available open access under the following conditions.  
 
Copyright © and all moral rights to the version of the paper presented here belong to the 
individual author(s) and/or other copyright owners. To the extent reasonable and 
practicable the material made available in WRAP has been checked for eligibility before 
being made available. 
 
Copies of full items can be used for personal research or study, educational, or not-for-profit 
purposes without prior permission or charge. Provided that the authors, title and full 
bibliographic details are credited, a hyperlink and/or URL is given for the original metadata 
page and the content is not changed in any way. 
 
Publisher’s statement: 
Please refer to the repository item page, publisher’s statement section, for further 
information. 
 
For more information, please contact the WRAP Team at: wrap@warwick.ac.uk. 
 
 1 
 
Equity-efficiency trade-offs associated with alternative approaches to deceased donor 
kidney allocation: a cost-effectivenesspatient-level simulation  
 
Bernadette Li, PhD 
Department of Health Services Research and Policy 
London School of Hygiene and Tropical Medicine 
London, UK 
 
John A. Cairns, MPhil 
Department of Health Services Research and Policy 
London School of Hygiene and Tropical Medicine 
London, UK 
 
Rachel J. Johnson, MSc 
NHS Blood and Transplant 
Bristol, UK 
 
Christopher J. E. Watson, MD 
Department of Surgery 
University of Cambridge and the NIHR Cambridge Biomedical Research Centre 
Cambridge, UK 
 
Paul Roderick, MD 
Primary Care and Population Sciences 
Faculty of Medicine 
University of Southampton 
Southampton, UK 
 
Gabriel C. Oniscu, MD 
Transplant Unit 
Royal Infirmary of Edinburgh  
Edinburgh, UK 
 
Wendy Metcalfe, MD 
Scottish Renal Registry 
Glasgow, UK 
 
 
Main - Marked Copy (To Include:Title page, Text, Abstract,
References, and Tables.)
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 2 
 
J. Andrew Bradley, PhD 
Department of Surgery 
University of Cambridge and the NIHR Cambridge Biomedical Research Centre 
Cambridge, UK 
 
Charles R. Tomson, DM 
Department of Renal Medicine 
Freeman Hospital 
Newcastle upon Tyne, UK  
 
Heather Draper, PhD 
Division of Health Sciences 
Warwick Medical School 
University of Warwick 
Coventry, UK 
 
John L. Forsythe, MD 
Transplant Unit 
Royal Infirmary of Edinburgh 
Edinburgh, UK  
 
Christopher Dudley, MD 
Richard Bright Renal Unit 
Southmead Hospital 
Bristol, UK 
 
Rommel Ravanan, MD 
Richard Bright Renal Unit 
Southmead Hospital 
Bristol, UK 
 
CORRESPONDENCE TO: 
Bernadette Li 
Department of Health Services Research and Policy 
London School of Hygiene and Tropical Medicine 
15-17 Tavistock Place, London WC1H 9SH, UK 
E-mail: bernadette.li@lshtm.ac.uk 
 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 3 
 
AUTHORSHIP 
BL and JAC participated in the development of the simulation model and analyses of data 
inputs. RJJ facilitated acquisition and interpretation of data from the UK Transplant Registry. 
All authors participated in the research design, performance of the research and writing of 
the article.  
Disclosure: The authors declare no conflicts of interests. 
Funding:  This work was funded by a National Institute for Health Research (NIHR) 
Programme Grant for Applied Research (RP-PG-0109-10116). 
  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 4 
 
ABSTRACT  
Background: The number of patients waiting to receive a kidney transplant outstrips the 
supply of donor organs. We sought to quantify trade-offs associated with different 
approaches to deceased donor kidney allocation in terms of quality-adjusted life years 
(QALYs), costs and access to transplantation.  
Methods: An individual patient simulation model was developed to compare five different 
approaches to kidney allocation, including the 2006 UK National Kidney Allocation Scheme 
(NKAS) and a QALY-maximisation approach designed to maximise health gains from a limited 
supply of donor organs. We used various sources of patient-level data to develop 
multivariable regression models to predict survival, health-state utilities and costs. We 
simulated the allocation of kidneys from 2200 deceased donors to a waiting list of 5500 
patients and produced estimates of total lifetime costs and QALYs for each allocation scheme.  
Results: Among patients who received a transplant, the QALY-maximisation approach 
generated 48,045 QALYs and cost £681 million while the 2006 NKAS generated 44,040 QALYs 
and cost £625 million. When also taking into consideration outcomes for patients who were 
not prioritised to receive a transplant, the 2006 NKAS produced higher total QALYs and costs 
and an incremental cost-effectiveness ratio of £110,741/QALY compared to the QALY-
maximisation approach.  
Conclusions: Compared to the 2006 NKAS, a QALY-maximisation approach makes more 
efficient use of deceased donor a limited supply of kidneys but reduces access to 
transplantation for older patients and results in greater inequity in the distribution of health 
gains between patients who receive a transplant and patients who remain on the waiting list.  
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ABBREVIATIONS 
EPTS, expected post-transplant survival  
HLA, human leukocyte antigen 
ICER, incremental cost-effectiveness ratio 
LYFT, life years from transplant 
NKAS, national kidney allocation scheme 
QALY, quality-adjusted life year 
UKKDRI, UK kidney donor risk index 
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INTRODUCTION 
In 2017, there were approximately 5200 patients waiting to receive a kidney transplant in 
the UK.1 Because the number of patients waiting to receive a transplant far outstrips the 
supply of organs from deceased donors, many countries have put in place allocation 
systems that make the criteria for prioritising potential recipients transparent and explicit.  
some form of rationing is inevitable. In many countries, the approach to rationing is made 
explicit through the design of a national kidney allocation scheme. In the UK, a matching 
system between recipients and deceased donors has been in place since 1972.2 The 
approach to kidney allocation in the UK is subject to continuous audit and review and over 
the decades, the national scheme has undergone a number of revisions to address and 
balance considerations of both improving transplant outcomes and promoting equity in 
access to transplantation.3-4  
Simulation modelling is a practical tool that can be used to evaluate or prospectively test the 
impact of potential changes to kidney allocation schemes.5-7 As part of the Access to 
Transplantation and Transplant Outcomes Measure (ATTOM) study, we conducted a 
simulation exercise to explore and compare alternative approaches to allocating kidneys 
from deceased donors in the UK context. We approached the development of the 
simulation model with three key objectives in mind: 
1. To simulate different approaches to kidney allocation that reflect varying degrees of 
emphasis on the competing objectives of efficiency (maximising health gains from scarce 
resources) and promoting equity in access to transplantation. 
2. To report outcomes for each kidney allocation scheme in terms of both quality-adjusted 
life years (QALYs) and costs. 
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3. To maximise use of information on individual patient and donor characteristics to inform 
the allocation process and to account for between-patient variability in the estimation of 
outcomes. 
Kidney allocation concepts of interest 
The last major revision to the UK kidney allocation scheme took place in 2006.4 In this 
simulation exercise, we compared the 2006 national kidney allocation scheme (NKAS) to 
several alternative approaches, with a particular interest in exploring the feasibility of 
designing an allocation scheme that maximises health gains, expressed in terms of QALYs, 
among transplant recipients from a fixed supply of donor kidneys. The design of a QALY-
maximisation allocation scheme was predicated on the following assumptions: 
1. For patients awaiting a transplant, there is a treatment alternative, namely dialysis.  
2. Not all donor kidneys will result in equally good survival outcomes. 
3. Not all potential recipients will derive the same survival benefit from a given donor 
kidney. 
In the QALY-maximisation scheme, for each donor kidney that becomes available, the 
simulation model estimates expected QALYs following transplant for each patient on the 
waiting list given the characteristics of both the patient and the donor kidney to be 
allocated. Next, the simulation model estimates expected QALYs for each patient on the 
waiting list if the patient were to remain on dialysis. After calculating the difference 
between expected QALYs following transplant and expected QALYs on dialysis, each kidney 
is allocated to the patient who is expected to gain the most as a result of receiving the 
transplant. Over the population of transplant recipients, this approach to allocation should 
yield the maximum total QALY gains for a fixed number of donor kidneys. This QALY-
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maximisation scheme is conceptually similar to the Life Years from Transplant (LYFT) 
calculation previously described by Wolfe et al., but in the current simulation exercise we 
used UK data sources and adopted a different method to extrapolate survival using flexible 
parametric survival analysis in order to calculate QALYs.8  
A new kidney allocation scheme based on the concept of longevity matching was introduced 
in the US in 2014. Under this concept, donor kidneys are risk-stratified using a scoring 
system in order to identify which kidneys are associated with better post-transplant survival. 
Similarly, potential recipients on the waiting list are risk-stratified based on estimates of 
their expected post-transplant survival (EPTS) score. The allocation policy then prioritises 
candidates in the top 20th percentile of EPTS scores to receive kidneys from the top 20% of 
donor kidneys.9 The cost implications of this new allocation policy in the US have been 
estimated.10 To test the concept of longevity matching in the UK context, we used a UK-
specific kidney donor risk index (UKKDRI)10 11 and developed a multivariable parametric 
model to estimate mean post-transplant survival for potential recipients based on an 
analysis of historical UK Transplant Registry data.11 12 A key difference between our 
approach to estimating recipient post-transplant survival and the EPTS score used in the US 
kidney allocation scheme is that our survival predictions also take into account two donor 
characteristics: age and history of hypertension. Thus, in our simulation exercise, recipient 
post-transplant survival estimates for both the QALY-maximisation and longevity matching 
allocation schemes are recalculated for each potential donor-recipient combination. 
In addition to exploring the concepts of QALY-maximisation and longevity matching, we 
included two other allocation concepts in our simulation exercise that were intended to 
reflect greater emphasis on the principle of equity in access to transplant: random allocation 
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and allocation based on waiting time. Table 1 provides an overview of all five allocation 
concepts explored in our simulation exercise.  
METHODS 
Characteristics of waiting list patients and donor kidneys 
To simulate the composition of the transplant waiting list, we obtained data on 1948 
prevalent listed patients who were recruited into the ATTOM study between November 
2011 and September 2013.13 14 Of these patients, 513 had received a previous transplant. In 
the absence of predictive survival models that would allow us to account for prior 
transplants, we excluded these patients from the simulation exercise leaving a sample of 
1435 patients, whose characteristics were replicated to make up a total waiting list of 5500 
patients, which reflected the size of the waiting list at the time the simulation model was 
designed (Table 2). During the simulation exercise, each time a patient received a 
transplant, a replacement was added to the waiting list to keep it constant at 5500 patients. 
For the donor dataset, we obtained characteristics of 2200 donors (4400 kidneys) from NHS 
Blood and Transplant based on a representative historical cohort reflecting the time period 
between January 2010 and December 2011 from NHS Blood and Transplant(Table 3).  
Characteristics of individual patients and donors were assigned at the point of entry into the 
model so that these characteristics could be used throughout the simulation to inform the 
allocation process as well as to estimate survival, costs and health-state utilities. Most 
patient characteristics, including comorbidities, were kept constant throughout the 
simulation, however three characteristics were updated as simulation time progressed; 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 10 
 
waiting time and time on dialysis were incremented on a daily basis, while patient age was 
incremented annually. 
Model structure and assumptions 
The simulation model was constructed using the software package SIMUL8 2015 
Professional version (SIMUL8 Corporation, Boston, MA, USA). At the start of the simulation, 
prevalent waiting list patients are loaded and held in a queue while donor kidneys are 
assumed to arrive at a fixed rate equivalent to 1200 deceased donors per year (Figure 1). 
The allocation process is triggered by the arrival of each donor kidney. Using Visual Logic, 
SIMUL8’s internal programming language, we are able to loop through patients on the 
waiting list to evaluate blood group and tissue compatibility for each potential donor-
recipient combination and perform the necessary calculations and scoring algorithms 
relevant to each allocation scheme of interest. In the model, we allowed for the possibility 
that no appropriate match is identified for a kidney from a donor with a rare blood or tissue 
type. This is unlikely to happen in practice but could occur in a small proportion of cases in 
our simulation because the composition of the waiting list was based on a limited sample of 
patients who were recruited into the ATTOM study. In the current UK allocation scheme, 
tissue matching between the donor and recipient is determined on the basis of human 
leukocyte antigens (HLA); patients are separated into one of four possible HLA mismatch 
levels from level 1 (000-mismatched) to level 4 (poorly matched). In current practice, 
patients with a level 4 HLA mismatch are not eligible to receive the donor kidney through 
the national allocation scheme.12 13 In order to maintain comparability between allocation 
schemes, we applied the same minimum criteria for blood group and HLA matching to all 
allocation schemes in the simulation exercise.  
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Once a match has been identified, the recipient and donor kidney are assembled into a 
single entity to simulate the transplantation event and moved to the next step in the 
simulation process to determine post-transplant survival and to estimate lifetime QALYs and 
costs. The model assumes only two events are possible following transplantation: graft 
failure, in which the transplanted kidney stops working, or patient death. These events are 
modelled as competing risks in which we randomly sample from the survival curve for each 
event and move the patient to the event with the earliest sampled time.14 15 If a patient 
experiences graft failure, we have assumed the patient returns to dialysis and faces the 
same mortality risk as a patient who has been on the waiting list and receiving dialysis for >3 
years. However, if the sampled value for time to death following graft failure is longer than 
the time the patient would have survived based on the previously sampled value to 
determine initial post-transplant outcomes, we replaced it with the lower value. We did not 
attempt to model repeat transplants in the simulation. 
The model was built by developing separate sections of Visual Logic code for each step in 
the allocation process so that, for example, the same procedure to evaluate blood group 
compatibility could be called at any point in the simulation for any of the five allocation 
schemes. Internal spreadsheets were used extensively to perform interim calculations at the 
patient level, which also facilitated model checks and step-by-step verification of the 
simulation process.  
Estimating life years, QALYs and costs 
Survival models 
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There are three survival models underpinning time-to-event calculations to estimate post-
transplant patient survival, post-transplant graft failure and waiting list survival at various 
points in the simulation. Each of these models was developed based on analysis of historical 
UK Transplant Registry data. Data on dialysis start dates were additionally obtained through 
linkage to the UK Renal Registry to inform the waiting list survival model. Models were fitted 
using flexible parametric survival analysis in order to facilitate:1516 
1. Extrapolation of survival curves to allow calculation of mean survival in years. 
2. Inclusion of relevant patient and donor characteristics as covariates to capture variability 
in our predictions of survival and by extension in our estimates of costs and QALYs. 
A more detailed description of the method used to fit the post-transplant patient survival 
model is described elsewhere.11 12 A summary of the patient and donor characteristics that 
were included as covariates in each of the final models is provided in Table S1. When the 
survival models were used as part of the allocation process to match recipients and donor 
kidneys (longevity matching and QALY-maximisation), they were applied deterministically to 
produce mean survival estimates. When the survival models were used to inform competing 
risks following transplantation in order to estimate lifetime QALYs and costs, we allowed for 
stochastic variation.  
Health-state utility estimates 
Health-state utility estimates for transplant recipient and patients on the waiting list were 
captured in the ATTOM study using the EQ-5D-5L questionnaire. We developed 
multivariable regression models to identify patient characteristics that led to variations in 
utility scores to inform quality-adjustment of survival estimates in the simulation model (see 
Table S2 for a list of characteristics included in the final models).16 17  
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Costs 
The costs of maintenance dialysis and transplant surgery were estimated in the simulation 
by applying fixed national tariffs.17 18 We estimated annual hospital costs using two-part 
regression models that were developed by analysing patient-level data from linkage of the 
Hospital Episode Statistics dataset to UK Renal Registry data.18 19 Hospital costs were 
captured by treatment modality (dialysis vs. transplantation) and by hospital setting 
(inpatient vs. outpatient) and regression models included a number of patient 
characteristics as covariates (Table S3a and Table S3b). For transplant recipients, the annual 
cost of maintenance immunosuppression assumed that patients received a combination of 
corticosteroids, a calcineurin inhibitor (ciclosporin or tacrolimus) and an antiproliferative 
agent (mycophenolate mofetil or azathioprine).2019 
Running the simulation 
For each allocation scheme, we performed three runs using a separate random number 
stream for each run. A single run ends when all 4400 donor kidneys have been allocated or 
removed from further consideration if no match has been identified. The proportion of 
donor kidneys for which no match was identified was approximately 1% across all simulation 
runs and therefore the number of patients who received a transplant was similar across 
allocation schemes.  
Although we are primarily interested in comparing total costs and QALYs across all 
transplant recipients resulting from the different allocation schemes, it is also important to 
consider the outcomes of those patients who did not receive a transplant within the time 
frame of the simulation. For these patients, we made a simplifying assumption that they 
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face a mortality risk equivalent to remaining on the waiting list until death and used this as 
the basis for projecting their lifetime costs and QALYs at the end of the simulation. QALYs 
and costs were both discounted at an annual rate of 3.5%.210 
For each allocation scheme, we report the characteristics of patients who received a 
transplant, the distribution of life years and QALYs for transplant recipients by age group 
and the total discounted costs and QALYs for patients who received a transplant, for 
patients who remained on the waiting list and for the overall cohort. To highlight the 
magnitude of trade-offs between efficiency and equity in access to transplantation, we also 
compare several key characteristics of patients who received a transplant under each 
scheme. 
 
RESULTS  
Cost-effectiveness results 
The motivation behind the QALY-maximisation approach is to allocate each donor organ in a 
way that maximises the potential gain in health among transplant recipients, in other words 
to make the most efficient use of a scarce supply of kidneys. Table 2 shows that for patients 
who received a transplant, this approach generated the most QALYs (48,045) and also led to 
the highest costs (£681 million). However, Table 2 also shows that patients who were not 
prioritised to receive a transplant and who remained on the waiting list had worse health 
outcomes and generated fewer total QALYs (20,504) compared to other allocation schemes.   
Taking into account total costs and QALYs for both transplant recipients and patients who 
remained on the waiting list, longevity matching produced the fewest QALYs (65,665) and 
the lowest costs (£1,473 million), while the 2006 NKAS produced the most QALYs (70,569) 
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and the highest costs (£1,722 million). While the longevity matching and QALY-maximisation 
schemes both generated more QALYs for transplant recipients than the 2006 NKAS, they 
generated far fewer QALYs for those patients who were assumed to remain on the waiting 
list. In incremental cost-effectiveness analysis, random allocation and waiting-time 
allocation were both dominated; that is to say, they were both less effective and more 
costly than at least one of the other allocation approaches. The comparison of the QALY-
maximisation approach to longevity matching generated an incremental cost-effectiveness 
ratio (ICER) of £8,751/QALY while the comparison of the 2006 NKAS to the QALY-
maximisation approach generated an ICER of £110,741/QALY (Figure 2). 
Access to transplantation 
To understand the impact of the different allocation schemes on access to transplantation, 
Table 3 4 reports the age, sex and diabetes status of patients who received a transplant. 
Moving along the equity-efficiency spectrum from random allocation towards allocation 
based on QALY-maximisation, there is a notable decrease in the average age of transplant 
recipients. Under random allocation, which preserves the composition of the original 
waiting list at the start of the simulation, 31% of transplant recipients were aged ≥60 years 
and above; under the QALY-maximisation approach, this proportion fell to just 4%. 
Allocation schemes that emphasised greater efficiency also resulted in a higher proportion 
of female transplant recipients and a lower proportion of transplant recipients with 
diabetes. 
Distribution of life years and QALYs 
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Table 5 shows mean survival (life years) and mean QALYs for each allocation scheme. The 
QALY-maximisation scheme resulted in the highest mean life years and QALYs for each 
transplant recipient (23.6 life years, 19.3 QALYs) but correspondingly the lowest mean life 
years and QALYs for patients who were not prioritised to receive a transplant (6.5 life years, 
5.1 QALYs). The waiting time allocation scheme resulted in the lowest mean life years and 
QALYs for each transplant recipient (17.1 life years, 13.9 QALYs) and also resulted in the 
smallest difference in survival for those who received a transplant compared to those who 
did not.  
Although the QALY-maximisation scheme resulted in the lowest proportion of patients aged 
≥60 years receiving a transplant (4%), those who did receive a transplant survived longer on 
average than patients aged ≥60 years under any of the other allocation schemes. This is 
because the QALY-maximisation scheme is selecting patients who are expected to live long 
enough to derive the biggest survival benefit from each donor kidney compared to 
remaining on dialysis.  
Cost-effectiveness results 
The motivation behind the QALY-maximisation approach is to allocate each donor organ in a 
way that maximises the potential gain in health among transplant recipients, in other words 
to make the most efficient use of a scarce supply of kidneys. Table 26 shows total QALYs and 
costs for the entire cohort of patients in the simulation. that for For patients who received a 
transplant, the QALY-maximisation is approach generated the mosthighest total QALYs 
(48,045) and also led to the highest costs (£681 million). However, Table 26 also shows that 
patients who were not prioritised to receive a transplant and who remained on the waiting 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
 17 
 
list had worse health outcomes and generated fewer total QALYs (20,504) compared to 
other allocation schemes.   
Taking into account total costs and QALYs for both transplant recipients and patients who 
remained on the waiting list, longevity matching produced the fewest QALYs (65,665) and 
the lowest costs (£1,473 million), while the 2006 NKAS produced the most QALYs (70,569) 
and the highest costs (£1,722 million). While the longevity matching and QALY-maximisation 
schemes both generated more QALYs for transplant recipients than the 2006 NKAS, they 
generated far fewer QALYs for those patients who were assumed to remain on the waiting 
list. In incremental cost-effectiveness analysis, random allocation and waiting-time 
allocation were both dominated; that is to say, they were both less effective and more 
costly than at least one of the other allocation approaches. The comparison of the QALY-
maximisation approach to longevity matching generated an incremental cost-effectiveness 
ratio (ICER) of £8,751/QALY while the comparison of the 2006 NKAS to the QALY-
maximisation approach generated an ICER of £110,741/QALY (Figure 2). 
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DISCUSSION 
The allocation of deceased donor kidneys to patients who are awaiting a transplant is 
constrained not only by a limited supply of kidneys but also, like all resource allocation 
decisions in healthcare, by a limited budget.  The emphasis of the literature and the debate 
about kidney allocation has historically focussed on donor organs as the only constraint, and 
in particular on the trade-off between maximising survival and ensuring equity in access to 
transplantation. In this research, we have explored a wider range of potential objectives in 
the design of a kidney allocation scheme and used simulation modelling to quantify the 
magnitude of trade-offs associated with moving from one allocation approach to another. In 
particular, this is the first patient-level simulation exercise to consider the costs associated 
with different approaches to kidney allocation in the UK and to report outcomes in terms of 
QALYs. 
The motivation for the simulation exercise described in this paper was not only to explore 
different allocation concepts from across the equity-efficiency spectrum, but also to 
improve our ability to estimate variability in outcomes resulting from different approaches 
to allocation using patient-level data. If alternative approaches to kidney allocation result in 
different patients receiving transplants, then an accurate comparison of the consequences 
of alternative allocation schemes depends on our ability to predict variability in outcomes 
dependent on individual patient characteristics. This simulation exercise relied on a number 
of rich sources of patient-level data including the ATTOM study, the UK Transplant Registry 
(held by NHS Blood and Transplant), Hospital Episode Statistics and the UK Renal Registry in 
order to develop predictive regression models to estimate survival, health-state utilities and 
costs. These predictive models were used not only to estimate QALYs and costs for 
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transplant recipients in all five allocation schemes but also as part of the criteria to inform 
the kidney allocation process for the longevity matching and QALY-maximisation schemes.  
Our research demonstrates the richness of information that can be generated from a 
patient-level simulation but we are cognisant that there are limitations to any modelling 
exercise. In particular, we made a number of assumptions with respect to the model 
structure, such as only considering first-time transplants and excluding paediatric patients 
as the latter group fell outside of the scope of the ATTOM study. The characteristics of the 
donors were based on a contemporaneous cohort with the waiting list patients in the 
ATTOM study but we have not attempted to model the consequences of the different 
allocation schemes if the composition of either the donor pool or the waiting list were to 
change significantly over time.  Another important simplifying assumption was that patients 
who were on the waiting list at the end of the simulation would not receive a transplant in 
the future. This assumption is unlikely to be met in practice. Survival on the waiting list is on 
average poorer than survival following transplant, so the likely effect of this assumption is 
that we have underestimated total QALYs for all allocation schemes. It is difficult to 
anticipate the net impact of this assumption on the cost-effectiveness results. Different 
allocation criteria will result in different types of patients receiving transplants and by 
corollary, the composition of patients who remain on the waiting list will also differ between 
schemes. Under the waiting-time allocation scheme, patients who remain on the waiting list 
at the end of the simulation would in practice still have a reasonable prospect of receiving a 
future transplant as their likelihood of being prioritised for transplant increases with time. In 
contrast, under the QALY-maximisation scheme, patients who remain on the waiting list at 
the end of the simulation may be less likely to receive a future transplant if their expected 
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QALY gains from transplant decrease over time relative to new patients joining the waiting 
list. Rather than attempt to apply different assumptions to each allocation scheme to 
project what proportion or which types of patients on the waiting list are likely to receive a 
future transplant at the end of the simulation, we chose to implement a standardised 
assumption so as not to confound our ability to observe and compare the effect of the 
different allocation schemes themselves. Given the importance of this assumption on 
estimates of QALYs and costs for the total patient population, future research should focus 
on testing alternative assumptions, for example by exploring if a non-terminating model 
could achieve a steady-state outcome that can be compared across allocation schemes over 
a long enough period of time. As with all simulation exercises, the need to make simplifying 
assumptions may limit the generalisability of the results to the real world context. With 
these caveats in mind, simulation modelling is still an important tool that can help increase 
our understanding of the potential consequences of different approaches to kidney 
allocation under the same set of conditions in comparison to each other.  
Although we chose to report lifetime QALYs and costs as the main outcomes of interest, this 
simulation exercise was not specifically designed with standard methods for cost-
effectiveness modelling at the forefront of our approach.221 There were both technical and 
philosophical reasons that contributed to this decision. During development of the 
simulation model, primary emphasis was placed on the design, feasibility and coding of the 
different allocation schemes. Each scheme requires the simulation model to loop through all 
patients on the waiting list in order to evaluate donor-recipient compatibility. In the case of 
the QALY-maximisation and longevity matching schemes, survival predictions take into 
account both recipient and donor characteristics and therefore need to be recalculated for 
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all 5500 patients on the waiting list each time a donor kidney enters the simulation. The 
computational burden of the allocation process itself led to long model running times even 
in the absence of introducing parameter uncertainty and therefore we were unable to 
perform full probabilistic sensitivity analysis. On a more philosophical note, kidney 
allocation represents a somewhat uniqueparticular resource allocation problem constrained 
not only by a finite healthcare budget but also by a limited supply of donor organs. 
Conventional cost-effectiveness methods focus on maximising health gains,232 but in the 
case of kidney allocation it is clear from current policy that maximising health gains is not 
the only objective. For this reason, we presented incremental cost-effectiveness results of 
allfor the five allocation schemes and but refrained from evaluating ICERs with respect to a 
specific threshold value. The results of this simulation exercise cannot answer the question 
about what the objectives of a national kidney allocation scheme should be, but nonetheless 
provide insight into the magnitude of QALY and cost differences to inform the discussion 
about trade-offs associated with alternative allocation concepts from across the equity-
efficiency spectrum. 
The QALY-maximisation approach to kidney allocation was designed to maximise health 
gains from a limited supply of donor kidneys. This approach yielded the most QALYs for 
transplant recipients but also resulted in a notable decrease in access to transplantation for 
older patients. Although the QALY-maximisation approach made more efficient use of a 
limited number of kidneys, it resulted in greater inequity in terms of both access to 
transplantation and the distribution of QALYs between transplant recipients and patients 
who remained on the waiting list.  
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A different kind of trade-off was evident when we considered the costs associated with each 
of the approaches to kidney allocation. The 2006 NKAS resulted in a modest increase in total 
QALYs across all patients compared to the QALY-maximisation approach but also incurred 
much higher total costs. If the 2006 NKAS is viewed as a compromise between equity and 
efficiency, then the results of this simulation provide an estimate of the additional cost to 
the NHS of maintaining greater equity in the allocation of deceased donor kidneys.  
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Table 1. Description of the five kidney allocation schemes included in the simulation 
exercise  
Allocation concept Description of allocation criteria considered in each scheme 
Random  Blood group compatibility and HLA match  
 Priority for HLA mismatch level 1 (000)  
 Taking the above criteria into account, allocate the kidney 
randomly  
Waiting time  Blood group compatibility and HLA match  
 Priority for HLA mismatch level 1 (000)  
 Taking the above criteria into account, allocate the kidney to the 
patient with the longest waiting time 
2006 NKAS12  Priority for HLA mismatch level 1 (000), taking into account 
whether or not patients are highly sensitised or HLA-DR 
homozygous 
 Within tiers, prioritise patients according to a points-based 
system based on: 
 waiting time 
 HLA match and age combined 
 donor-recipient age difference 
 location of patient relative to donor 
 HLA-DR homozygosity 
 HLA-B homozygosity 
 blood group match  
Longevity matching  For each donor kidney, estimate expected post-transplant 
survival for each patient on the waiting list  
 If the donor kidney has a UKKDRI score in the top 20%, then 
20% of patients with the longest expected post-transplant 
survival are prioritised to receive the kidney 
 Taking the above criteria into account, allocate the kidney 
according to the 2006 NKAS  
QALY-maximisation  Blood group compatibility and HLA match  
 Priority for HLA mismatch level 1 (000)  
 For each donor kidney, estimate expected post-transplant 
QALYs for each patient and expected QALYs if each patient were 
to remain on the waiting list (on dialysis) 
 Taking the above criteria into account, allocate the kidney to the 
patient with the biggest expected QALY gain from transplant 
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Table 2. Characteristics of the recipient cohort (n=5500) used in the simulation model 
 n (%) 
Age (years)  
18-29  369 (6.7%) 
30-39 708 (12.9%) 
40-49 1,245 (22.6%)  
50-59 1,576 (28.7%) 
≥60 1,602 (29.1%) 
Sex  
Female  2,320 (42.2%) 
Ethnicity   
White 4,017 (73.0%) 
Asian 727 (13.2%) 
Black  626 (11.2%) 
Other 140 (2.6%) 
Blood group  
O 3,135 (57.0%) 
A 1,590 (28.9%) 
B 684 (12.4%) 
AB 91 (1.7%) 
Highly sensitised 468 (8.5%) 
Primary renal diagnosis  
Diabetes 826 (15.0%) 
Polycystic kidney disease 82 (1.5%) 
Comorbidities  
Ischaemic heart disease 475 (8.6%) 
Congestive heart failure 178 (3.2%) 
Peripheral vascular disease 199 (3.6%) 
Cerebrovascular disease 293 (5.3%) 
Respiratory disease 447 (8.1%) 
Liver disease 74 (1.4%) 
Malignancy 262 (4.8%) 
Mental illness 403 (7.3%) 
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Smoker 730 (13.3%) 
Years on dialysis at time of listing  
Pre-dialysis 2,413 (43.9%) 
<1 year 1,490 (27.1%) 
1-3 years 879 (16.0%) 
> 3 years 263 (4.8%) 
Missing  455 (8.3%) 
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Table 3. Characteristics of the donor cohort (n=2200) used in the simulation model 
 n (%) 
Age (years)  
<30 394 (17.9%) 
30-39 283 (12.9%) 
40-49 503 (22.9%) 
50-59 548 (24.9%) 
≥60 472 (21.5%) 
Blood group   
O 1,024 (46.5%) 
A 892 (40.5%) 
B 197 (9.0%) 
AB 87 (4.0%) 
History of hypertension 499 (22.7%) 
UK kidney donor risk index  
High risk (≥1.35) 582 (26.5%) 
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Table 4. Summary of characteristics of patients who received a transplant under each 
allocation scheme  
 Random  Waiting time 2006 NKAS 
Longevity 
matching 
QALY-
maximisation 
Mean age - years 
(SD) 
51.4 (12.8) 52.5 (12.3) 46.6 (12.5) 46.3 (12.6) 41.8 (10.7) 
Age group - years      
18-29  7% 5% 10% 10% 15% 
30-39 12% 11% 19% 20% 27% 
40-49 22% 21% 28% 29% 36% 
50-59 28% 30% 25% 23% 18% 
≥60 31% 33% 18% 18% 4% 
Female 42% 43% 44% 44% 50% 
Diabetes 15% 15% 14% 14% 11% 
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Table 5. Average undiscounted life years and QALYs per patient for each allocation scheme  
 Random allocation  Waiting time 2006 NKAS  Longevity matching  QALY-maximising  
Life years Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI 
Transplant recipients (by age group)           
18-29  27.2 (24.7, 29.7) 27.2 (24.0, 30.3) 32.8 (30.3, 35.3) 31.5 (29.3, 33.7) 29.2 (27.3, 31.2) 
30-39 26.5 (24.6, 28.4) 25.4 (23.5, 27.3) 29.2 (27.7, 30.8) 30.1 (28.6, 31.7) 27.5 (26.2, 28.8) 
40-49 23.4 (22.3, 24.6) 22.2 (21.0, 23.3) 23.4 (22.4, 24.5) 22.6 (21.6, 23.6) 23.4 (22.5, 24.4) 
50-59 15.2 (14.5, 15.9) 15.0 (14.3, 15.7) 14.5 (13.8, 15.2) 14.5 (13.7, 15.2) 15.6 (14.7, 16.6) 
>60 11.2 (10.7, 11.6) 11.4 (11.0, 11.9) 10.7 (10.2, 11.3) 11.0 (10.4, 11.6) 13.2 (11.5, 14.8) 
Transplant recipients (all) 18.0 (17.5, 18.5) 17.1 (16.7, 17.6) 21.1 (20.5, 21.7) 21.2 (20.7, 21.8) 23.6 (23.0, 24,2) 
No transplant (all) 8.9 (8.8, 9.1) 9.0 (8.9, 9.1) 9.0 (8.9, 9.1) 6.8 (6.7, 6.9) 6.5 (6.4, 6.6) 
           
QALYs Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI Mean 95% CI 
Transplant recipients (by age group)           
18-29  22.4 (20.4, 24.5) 22.4 (19.8, 24.9) 27.1 (25.0, 29.2) 26.0 (24.1, 27.8) 24.1 (22.5, 25.7) 
30-39 21.4 (19.9, 22.9) 20.6 (19.1, 22.2) 23.8 (22.5, 25.1) 24.5 (23.2, 25.8) 22.4 (21.3, 23.5) 
40-49 18.9 (18.0, 19.9) 17.9 (17.0, 18.8) 18.9 (18.0, 19.8) 18.3 (17.5, 19.1) 19.1 (18.3, 19.9) 
50-59 12.3 (11.7, 12.9) 12.1 (11.6, 12.7) 11.7 (11.1, 12.3) 11.7 (11.1, 12.3) 12.7 (12.0, 13.5) 
>60 9.0 (8.7, 9.4) 9.2 (8.8, 9.6) 8.7 (8.2, 9.1) 8.9 (8.4, 9.4) 10.7 (9.3, 12.0) 
Transplant recipients (all) 14.6 (14.2, 15.0) 13.9 (13.5, 14.2) 17.1 (16.6, 17.6) 17.2 (16.8, 17.7) 19.3 (18.8, 19.8) 
No transplant (all) 6.9 (6.8, 7.0) 6.9 (6.9, 7.0) 7.0 (6.9, 7.1) 5.2 (5.1, 5.3) 5.1 (5.0, 5.1) 
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Table 26. Cost-effectiveness results for transplant recipients, patients who remained on the waiting listpatients who did not receive a 
transplant and all patients combined 
 
Transplant recipients 
Waiting-list patientsNo 
transplant 
All patients 
Absolute cCosts 
Absolute 
QALYs 
Absolute cCosts 
Absolute 
QALYs 
Absolute cCosts 
Absolute 
QALYs 
Incremental 
costs 
Incremental 
QALYs 
ICER 
Longevity 
matching 
£632,382,864 44,704 £841,064,018 20,961 £1,473,446,881 65,665 - - - 
QALY-
maximisation 
£680,552,945 48,045 £818,130,717 20,504 £1,498,683,661 68,549 £25,236,780 2884 £8,751 
Random £590,657,199 40,236 £1,088,809,775 26,328 £1,679,466,974 66,563 £180,783,313 -1986 Dominated 
Waiting time £584,489,615 39,496 £1,099,379,875 26,572 £1,683,869,490 66,068 £185,185,829 -2481 Dominated 
2006 NKAS £624,864,970 44,040 £1,097,473,021 26,529 £1,722,337,991 70,569 £223,654,330 2020 £110,741 
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Table 3. Summary of characteristics of patients who received a transplant under each 
allocation scheme  
 Random  Waiting time 2006 NKAS 
Longevity 
matching 
QALY-
maximisation 
Mean age - years 
(SD) 
51.4 52.5 46.6 46.3 41.8 
Age group - years      
18-29  7% 5% 10% 10% 15% 
30-39 12% 11% 19% 20% 27% 
40-49 22% 21% 28% 29% 36% 
50-59 28% 30% 25% 23% 18% 
≥60 31% 33% 18% 18% 4% 
Female 42% 43% 44% 44% 50% 
Diabetes 15% 15% 14% 14% 11% 
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Figure 1. Structure of the simulation model  
 
Figure 2. Cost-effectiveness plane showing the relative positions of the 5 allocation schemes 
in terms of both total costs (vertical axis) and total QALYs (horizontal axis) for all patients 
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